Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI

Tayyar Akbulut; Ramazan Asoğlu; Mahmut Özdemir; Nesim Aladağ; İrem Karauzum; Abdulcebbar Şipal; Kurtuluş Karaüzüm

doi:10.28982/josam.804767

Authors

Tayyar Akbulut https://orcid.org/0000-0002-5890-8420
Ramazan Asoğlu https://orcid.org/0000-0002-4777-1166
Mahmut Özdemir https://orcid.org/0000-0002-0021-3415
Nesim Aladağ https://orcid.org/0000-0003-2346-1152
İrem Karauzum https://orcid.org/0000-0002-8015-6253
Abdulcebbar Şipal https://orcid.org/0000-0002-6379-8342
Kurtuluş Karaüzüm https://orcid.org/0000-0002-7088-1590

DOI:

https://doi.org/10.28982/josam.804767

Keywords:

Omentin, acute coronary syndrome, CKMB, troponin, myoglobin

Abstract

Aim: Acute coronary syndrome (ACS) is an ischemic cardiac disease that could result in myocardial necrosis with prolonged ischemia. Omentin (intelectin-1) is a new biomarker that is released from adipose tissue. It is associated with coronary artery disease (CAD) and has an acute ischemic injury-reducing effect. This study aimed to assess the omentin levels in patients with unstable angina pectoris (USAP), Non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevated myocardial infarction (STEMI). Methods: This case-control prospective study included 59 patients with ACS and 22 healthy subjects. MB fraction of creatine kinase (CKMB), troponin, myoglobin, and omentin levels were measured from venous blood obtained from each patient within six hours after the onset of symptoms. Plasma omentin levels were determined with an omentin enzyme-linked immunosorbent assay kit. Results: The patient group was older than the control group (P<0.05) but there was no difference between the groups in terms of gender (P>0.05). The rate of smoking was higher in the patient group, and the patient group was heavier than the control group (P>0.05). Omentin levels were similar in ACS patients and control subjects (6.0 (1.7) vs. 6.3 (1.3), P=0.40). There was no significant correlation among CKMB, troponin, myoglobin, and omentin levels. Moreover, omentin levels were similar in ACS subgroups (P=0.58). There was no significant correlation between body mass index and omentin levels (r =-0.186, P=0.09). Conclusion: This study revealed that there was no significant relationship between omentin and myoglobin levels in ACS patients. The potential usefulness of blood concentrations of omentin levels in understanding the relationship with ACS warrants further studies.

Downloads

Download data is not yet available.

References

Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.

Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007;50(22):2173–95.

Anwaruddin S, Januzzi Jr JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. American journal of clinical pathology. 2005;123(1):140–5.

Koleva DI, Orbetzova MM, Atanassova PK. Adipose Tissue Hormones and Appetite and Body Weight Regulators an Insulin Resistance/ Folia medica. 2013;55(1):25–32.

Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2005;1732(1–3):96–102.

Sengul E, Duygulu G, Dindar S, Bunul F. Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease. Renal failure. 2013;35(8):1089–93.

Tan Y-L, Zheng X-L, Tang C-K. The protective functions of omentin in cardiovascular diseases. Clinica Chimica Acta. 2015;448:98–106.

Jaikanth C, Gurumurthy P, Cherian K, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Experimental and Clinical Endocrinology & Diabetes. 2013;121(07):377–83.

Duan X-Y, Xie P-L, Ma Y-L, Tang S-Y. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino acids. 2011;41(5):1223–31.

Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513–21.

Shang F-J, Wang J-P, Liu X-T, Zheng Q-S, Xue Y-S, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16(8):657–62.

Zhong X, Zhang H, Tan H, Zhou Y, Liu F, Chen F, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica. 2011;32(7):873–8.

Kadoglou NP, Tahmatzidis DK, Giannakoulas C, Kapelouzou A, Gkontopoulos A, Parissis J, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. Journal of Cardiovascular Medicine. 2015;16(5):341–6.

Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase-and Akt-dependent mechanisms. Journal of the American College of Cardiology. 2014;63(24):2722–33.

Türkcü FM, Şahin A, Cingü AK, Kaya S, Yüksel H, Cinar Y, et al. Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253(9):1565–8.

Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovascular diabetology. 2014;13(1):84.

Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetology & metabolic syndrome. 2012;4(1):37.

Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and biophysical research communications. 2011;408(2):339–43.

Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. Journal of Biological Chemistry. 2012;287(1):408–17.

De Jager SC, Pasterkamp G. Atheroprotective properties of human Omentin-1 in experimental atherosclerosis. 2016;???:???.

Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, et al. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovascular diabetology. 2011;10(1):87.

Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nature Reviews Endocrinology. 2015;11(6):363.

Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications. 2010;393(4):668–72.

Moreno‐Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández‐Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity. 2011;19(8):1552–9.

Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovascular diabetology. 2016;15(1):90.

Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama T, et al. Counteractive effects of omentin-1 against atherogenesis. Cardiovascular research. 2016;110(1):118–28.

Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219(2):811–4.

Uemura Y, Shibata R, Kanemura N, Ohashi K, Kambara T, Hiramatsu-Ito M, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. The FASEB Journal. 2015;29(1):141–51.

Zhu Y, Hu C, Du Y, Zhang J, Liu J, Cheng G, et al. Time-Dependent Change in Omentin-1 Level Correlated with Early Improvement of Myocardial Function in Patients with First Anterior ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Journal of atherosclerosis and thrombosis. 2019;26(10):856–67.

Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis. 2016;251:299–304.

Wu S-S, Liang Q-H, Liu Y, Cui R-R, Yuan L-Q, Liao E-Y. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. International journal of endocrinology. 2013;2013.